RGENRepligen Corporation
Is it growing?
Neither accelerating nor breaking down: revenue growing +16% year on year and operating margin widening (+12.1 points), but earnings down −381% year on year.
Trailing-twelve-month revenue vs a year earlier, from the company's own filings. Five-year pace: +9% a year.
Trailing-twelve-month earnings per share against a year earlier. Growing slower than revenue, so the growth is costing something.
Trailing-twelve-month operating margin, 8.2% now against -3.8% a year earlier.
All from SEC EDGAR, as of Jun 30, 2026.
Against the whole market›
Percentile against every name Ryufin tracks. Higher is better; the tick marks the middle of the market. Context, not one of the checks above.
Where this answer is blind. These are trailing numbers from the filings, not forecasts: an acquisition or a one-off year can flatter them, so check the quarters.
Is RGEN growing?
Repligen Corporation has grown revenue 3.3% a year over three years and 9.1% a year over five, with earnings per share compounding at −31%.
Revenue growth, 3-year annual rate · Medical Instruments & Supplies median +9.8% · growing slowly · compounded from trailing twelve-month revenue
- Revenue growth, 5-year rate
- +9.1%
Revenue growth, 5-year rate · +3.3% over three · growth has slowed since the five-year average
- Earnings per share, 3-year rate
- −31%
Earnings per share, 3-year rate · revenue +3.3% · earnings lagged revenue: the growth is costing something
- Years of annual history on file
- 16
Years of annual history on file · FY2009 to FY2025, as filed
Details›
- Revenue FY2021
- $671M
- Revenue FY2022
- $802M
- Revenue FY2023
- $632M
- Revenue FY2024
- $634M
- Revenue FY2025
- $738M
Annual income statements as filed with the SEC.
Medical Instruments & Supplies
Ranks #11 of 21 by RyuScore